Related StoriesUAMS researchers report positive results from dealing with Metastatic Merkel-cell carcinoma with idelalisib drugFDA, EMA acknowledge filing applications for Boehringer Ingelheim's afatinib to take care of sufferers with advanced SCC of the lungArgos Therapeutics begins AGS-003 clinical trial in individuals with metastatic renal cell carcinomaThe 33 thymic carcinoma patients had a target response rate of 30 percent, which increased to 42 percent when just the patients who hadn’t received chemotherapy previously were considered. The ORR was 17 percent for the 18 thymoma patients included in this phase II trial. After a median follow-up of two years, median progression-free of charge survival was the same for both sets of patients, at 7.6 months. This compares favourably with the median PFS accomplished with other regimens in thymic carcinoma sufferers, but is significantly less than that accomplished in earlier invasive thymoma research, say the experts.Viale, as they seek updates from both journals geared to nurses and journals targeted to physicians. My hope is normally that The Journal of the Advanced Practitioner in Oncology provides our visitors with useful medical and professional information that will make them better equipped to look after their patients. Cold Springtime Publishing is quite fortunate to announce Pamela Viale as the Editor-in-Chief of The Journal of the Advanced Practitioner in Oncology, said John A. Gentile, Jr., Publisher of the journal. Her experience – – as a clinician, researcher, educator, and writer – – makes her the ideal candidate to business lead this publication. .. Chinese government cafeterias go non-GMO; public schoolchildren still being fed poisons Outrage erupted in the health world following China’s Ministry of Education recently declared that it does not serve genetically modified organisms to diners at its cafeteria.